An Open-Label, Randomized, Five Period Crossover Study to Estimate the Relative Bioavailability of Five Formulations of 400mg SB-751689 [ronacaleret] (a Calcium-Sensing Receptor Antagonist) Administered as a Single Oral Dose to Healthy Postmenopausal Females.
Phase of Trial: Phase I
Latest Information Update: 20 May 2009
At a glance
- Drugs Ronacaleret (Primary)
- Indications Postmenopausal osteoporosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 12 Nov 2007 New trial record.